Proceedings from the fourth in a series of 11 integrated
webinars held in association with the 2020 ONS Annual Congress.
Featuring perspectives from Ms Amy Goodrich, Dr Brad S Kahl, Ms
Robin Klebig and Dr Jeff Sharman.
Introduction (00:00)
Clinical presentation of chronic lymphocytic leukemia (CLL) and
biomarkers predictive of response (4:58)
Differences in clinical manifestation between CLL and small
lymphocytic lymphoma; educating the asymptomatic patient about the
benefits of watching and waiting (12:49)
Counseling patients with CLL about the risks and benefits of
acalabrutinib/obinutuzumab (18:47)
Mechanism of action, side effects and optimal integration of
novel BTK and Bcl-2 inhibitors for CLL (26:22)
Caring for patients on ibrutinib therapy; role of the oncology
nurse in providing emotional and psychological support (36:56)
Communicating the significance of clinical trial participation
to patients with CLL; results from the Phase III CLL14 trial
assessing fixed-duration venetoclax/obinutuzumab as up-front
therapy (46:17)
Optimal use of venetoclax for CLL; patient education about,
monitoring for and management of tumor lysis syndrome (54:53)
Selection and duration of front-line therapy for patients with
CLL (1:03:41)
Monitoring patients receiving venetoclax to prevent tumor lysis
syndrome (1:15:07)
Emerging data with the use of BTK inhibitor therapy for
patients with COVID-19 (1:19:45)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.